Ventana gains access to Molecular's HPV (Human Papilloma Virus) test
This article was originally published in Clinica
Ventana Medical Systems aims to add to its human papillomavirus (HPV) portfolio by acquiring a licence to Molecular Diagnostics' In-Cell HPV test for an undisclosed amount and royalties. The product is a bio-molecular assay for the detection of E6 and E7 HPV proteins.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.